Ovation
Contact
Description
This is an open-label, Phase 3 clinical trial evaluating the efficacy of Tofacitinib based on remission in children with moderate to severe ulcerative colitis. The effects will be evaluated during an induction, maintenance, and extension period of taking the medication. Physical exams, blood and stool sample collection, and sporadic endoscopic evaluation are planned to take place throughout these periods.
Eligibility and criteria
IRB Number:
20-018113
Eligible age range:
Clinical trial phase:
Phase III
Official title:
What to expect
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.